

# Video Transcript: MES and the Challenges Facing Life Sciences

## Understanding MES

**John Seffernick:** "MES is a way for our clients to create a record of the product that they made. Very simply put, MES allows you to digitally record how you manufactured your product and also from a quality standpoint, make sure that you're able to manufacture the product in a way that meets all of the quality criteria for the product."

**Chris Puzzo:** "MES is an orchestration solution for your manufacturing operations. Traditionally, that's been a solution based around your manufacturing process. But I think as we move forward, the industry is starting to change to something that's more operator and experience focused rather than process focused."

## Challenges in Life Sciences

**Steve Britton:** "What I'm seeing is that the definition that was made 40 years ago doesn't meet the needs that manufacturing operations has today, which is where we're seeing the emergence of software companies developing new tech, new platforms that work in the operations space, some of which call themselves MES, some of which don't. And in most cases, these new platforms, they don't fit snugly in that box that was defined as MES."

## Adapting for the Future

**Matt Heller:** "Flexibility is another factor. It's just important to be able to change your process quickly and with a lot of agility."

**Jay Upadhyay:** "The biggest piece is legacy. MES has been designed based on the industry, which for like 20 years ago or 15 years ago, where it's a large-scale deployment. The new way is, how we can implement faster in small timeframe and get the better results to address some specific small issues."

**Tim Adkins:** "The older systems require a lot more configuration time. The expertise, the technical expertise to do that is much greater, much higher level of expertise required where the newer ones are low-code, no-code configuration."

**Samantha Szatek:** "The first composable MES app-based gene therapy. This isn't only exciting because there are not many approved gene therapies in the world, but then to take it to the next step by deploying a new technology that's never been done and GMP manufacturing, when it comes to MES, this is even more exciting. So Zaether being on the forefront of that, I think is the first step of many for what we'll see in the future."